SRT 1460
Modify Date: 2025-08-22 19:34:16
SRT 1460 structure
|
Common Name | SRT 1460 | ||
|---|---|---|---|---|
| CAS Number | 925432-73-1 | Molecular Weight | 507.60 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C26H29N5O4S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of SRT 1460SRT 1460, a potent Sirtuin-1 (SIRT1) activator with an EC1.5 value of 2.9 μM, shows good selectivity for activation of SIRT1 versus SIRT2 and SIRT3 (EC1.5 > 300 μM), and is more potent than Resveratrol and the closest sirtuin homologues[1]. |
| Name | 3,4,5-trimethoxy-N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]benzamide |
|---|---|
| Synonym | More Synonyms |
| Description | SRT 1460, a potent Sirtuin-1 (SIRT1) activator with an EC1.5 value of 2.9 μM, shows good selectivity for activation of SIRT1 versus SIRT2 and SIRT3 (EC1.5 > 300 μM), and is more potent than Resveratrol and the closest sirtuin homologues[1]. |
|---|---|
| Related Catalog | |
| Target |
SIRT1:2.9 μM (EC1.5) |
| In Vitro | SRT 1460 (2-6 μM; 72 hours) inhibits cell viability in a dose-dependent manner, with all pancreatic cancer cells being more sensitive than the control HPDE cell. The IC50s of those cells are: Patu8988t, 1.62±0.13 μM; SU86.86, 2.31±0.23 μM; Panc-1, 0.66 ±0.02 μM; HPDE, 2.39±0.29 μM[2]. SRT 1460 (5 μM; 16 hours) increases expression of the autophagy marker LC3-II[2]. Cell Viability Assay[2] Cell Line: Patu8988t (pancreatic cancer cells), Panc-1 (pancreatic cancer cells), SU86.86 (pancreatic cancer cells), HPDE cells Concentration: 2 μM, 4 μM, 6 μM Incubation Time: 72 hours Result: Inhibited cell viability in a dose-dependent manner, with all pancreatic cancer cells being more sensitive than the control HPDE cell. The IC50s of those cells were: Patu8988t, 1.62±0.13 μM; SU86.86, 2.31±0.23 μM; Panc-1, 0.66 ±0.02 μM; HPDE, 2.39±0.29 μM. Western Blot Analysis[2] Cell Line: Patu8988t cells Concentration: 5 μM Incubation Time: 16 hours Result: SRT1460 increased expression of the autophagy marker LC3-II. |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Molecular Formula | C26H29N5O4S |
| Molecular Weight | 507.60 |
| Exact Mass | 507.194031 |
| PSA | 117.60000 |
| LogP | 3.88 |
| Index of Refraction | 1.669 |
| InChIKey | SBEWVVLMFLTQFE-UHFFFAOYSA-N |
| SMILES | COc1cc(C(=O)Nc2ccccc2-c2cn3c(CN4CCNCC4)csc3n2)cc(OC)c1OC |
| Hazard Codes | Xi |
|---|---|
| HS Code | 2934100090 |
| HS Code | 2934100090 |
|---|---|
| Summary | 2934100090 other compounds containing an unfused thiazole ring (whether or not hydrogenated) in the structure VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:20.0% |
| 3,4,5-Trimethoxy-N-{2-[3-(1-piperazinylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl}benzamide |
| Benzamide, 3,4,5-trimethoxy-N-[2-[3-(1-piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]- |
| 3,4,5-trimethoxy-N-{2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl}benzamide |
| 3,4,5-trimethoxy-N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)benzamide |
| SRT-1460 |